Noxopharm is a clinical-stage drug development company focused on creating treatments for various types of solid tumor cancers and septic shock. The company's pipeline drug candidate, Veyonda, is currently being trialed to treat several types of cancer. Additionally, Noxopharm's R&D program is working on developing later generation drug candidates to meet unmet medical needs. The company has offices in Sydney and New York, making it a global player in the biotech industry.
Noxopharm's ticker is NOX
The company's shares trade on the ASX stock exchange
They are based in Chatswood, Australia
There are 11-50 employees working at Noxopharm
It is http://www.noxopharm.com
Noxopharm is in the Healthcare sector
Noxopharm is in the Biotechnology industry
The following five companies are Noxopharm's industry peers: